ARBUTUS BIOPHARMA CORP NPV financial statements, including revenue, expenses, profit, and loss

The total revenue of 0SGC for the last quarter is 2.15 M USD, and it's 53.95% lower compared to the previous quarter. The net income of Q4 23 is -19.31 M USD.